Genomic Profiling and Matched Therapy for Recurrent or Metastatic Salivary Gland Neoplasms
This is a study of select drug therapies in patients with salivary gland cancer. The study
has two phases: a molecular profiling phase (phase 1) and a treatment phase (phase 2).
In molecular profiling phase of the study, participants will provide a sample of their tumour
tissue to test for changes in certain genes that show whether certain drug treatments will
be more useful than others.
Once participants have undergone molecular profiling, they will be offered a drug treatment
depending on the results. Certain drug treatments are designed to target certain gene
changes. If there is a matching drug treatment, participants will be offered that treatment
(either outside a clinical trial or within a clinical trial). If there are no gene changes
or there are changes to genes were there are no drug treatments available for those certain
changes, participants will be offered the study drug, Selinexor.
Cancer is the uncontrolled growth of cells. Research shows that one way cancer cells can
grow uncontrollably is when certain proteins, called exporter proteins, are present in high
levels in the body. These proteins prevent certain other proteins important in protecting
cells from becoming cancerous and important in the controlling the growth of cells, from
working. The study drug Selinexor is new class of drug called Selective Inhibitor of Nuclear
Export (SINE) that blocks the exporter proteins from working which may allow the other
proteins to work and slow or stop tumours from growing.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society